and actual TO of a company.
Dermavant Sciences recently sold $1.2B (usd) oct 2024 = $1.9B AUD
VTAMA, Dermavant's flagship product, is a non-steroidal topical treatment approved for plaque psoriasis in adults. In the fiscal year ending March 31, 2024, VTAMA generated $75.1 million in revenue ($116m AUD)
after 9 weeks we are already 30% there.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $617.6M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.0¢ | 31.5¢ | $1.783M | 5.561M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 460766 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 19200 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |